KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Intangibles (2016 - 2025)

Historic Change in Intangibles for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $15.0 million.

  • Travere Therapeutics' Change in Intangibles rose 8369.14% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 5140.3%. This contributed to the annual value of $36.2 million for FY2024, which is 1293.31% down from last year.
  • Latest data reveals that Travere Therapeutics reported Change in Intangibles of $15.0 million as of Q3 2025, which was up 8369.14% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Change in Intangibles ranged from a high of $27.3 million in Q1 2023 and a low of $3.8 million during Q2 2023
  • For the 5-year period, Travere Therapeutics' Change in Intangibles averaged around $8.6 million, with its median value being $6.5 million (2024).
  • As far as peak fluctuations go, Travere Therapeutics' Change in Intangibles skyrocketed by 43226.25% in 2023, and later tumbled by 7634.71% in 2024.
  • Travere Therapeutics' Change in Intangibles (Quarter) stood at $5.0 million in 2021, then fell by 17.42% to $4.2 million in 2022, then skyrocketed by 32.11% to $5.5 million in 2023, then soared by 75.17% to $9.6 million in 2024, then soared by 56.05% to $15.0 million in 2025.
  • Its Change in Intangibles was $15.0 million in Q3 2025, compared to $12.1 million in Q2 2025 and $11.8 million in Q1 2025.